Serotonin reuptake inhibitors, weak

Name: Sulfonamide-derived drugs (non-antibacterial)
Creator: Jason Cafer, MD

Drugs with measurable but clinically marginal SERT blockade (serotonicity rating 1): the effect is real at the transporter and rarely matters at the bedside
Separated from the main SRI row so that a weak binder is never counted as a serotonin-toxicity partner
The peg is drawn small and, where Gillman disputes the clinical reuptake inhibition, carries an asterisk
Not a reason to withhold an MAOI on its own; the combination verdict counts only ratings of 2 or more

Class at a glance

Drugs with measurable but clinically marginal SERT blockade (serotonicity rating 1): the effect is real at the transporter and rarely matters at the bedside
Separated from the main SRI row so that a weak binder is never counted as a serotonin-toxicity partner

The peg is drawn small and, where Gillman disputes the clinical reuptake inhibition, carries an asterisk
Not a reason to withhold an MAOI on its own; the combination verdict counts only ratings of 2 or more

Does a weak SRI rating block an MAOI?
No — the interaction verdict counts SRI ratings of 2 or more; a 1 is measurable binding without clinical reuptake inhibition.